Biocytogen and Hansoh Pharma Announce an Antibody License Agreement

Biocytogen Pharmaceuticals (Beijing), a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMice™ Platforms and Hansoh Pharmaceutical Group Company, a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, has announced an antibody collaboration, assignment and exclusive license agreement.

Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally. Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.

“We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China. The licensed antibodies were selected from Biocytogen’s Project Integrum programs and generated from our proprietary fully human antibody RenMice™ target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Thanks to Hansoh Pharma’s recognition of our RenMice™ platforms and Project Integrum. We believe Hansoh Pharma’s strong R&D, manufacturing and commercialization capabilities will accelerate the development of RenMice™-derived antibody molecules and bring the benefits to patients worldwide.”